On a winning streak, Heron rockets up 30% on PhIIb pain drug data
More than doubling its stock since the first of the year, San Diego’s Heron Therapeutics reported yet another slam dunk Thursday morning with news that its pain drug delivered in two more indications. That’s after the company reported stellar Phase III data just three months ago, and a FDA OK on a different drug before that.
Heron’s investors are pleased with the news, with the company’s stock $HRTX jumping 30% in pre-market trading.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.